- Home
- TPG vs CYTK Comparison
TPG vs CYTK Comparison
Compare TPG & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPG
- CYTK
- Stock Information
- Founded
- TPG 1992
- CYTK 1997
- Country
- TPG United States
- CYTK United States
- Employees
- TPG N/A
- CYTK N/A
- Industry
- TPG Investment Managers
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- TPG Finance
- CYTK Health Care
- Exchange
- TPG Nasdaq
- CYTK Nasdaq
- Market Cap
- TPG 7.0B
- CYTK 5.7B
- IPO Year
- TPG 2022
- CYTK 2004
- Fundamental
- Price
- TPG $67.03
- CYTK $45.74
- Analyst Decision
- TPG Buy
- CYTK Buy
- Analyst Count
- TPG 13
- CYTK 15
- Target Price
- TPG $60.75
- CYTK $83.64
- AVG Volume (30 Days)
- TPG 952.8K
- CYTK 1.2M
- Earning Date
- TPG 02-11-2025
- CYTK 02-25-2025
- Dividend Yield
- TPG 2.27%
- CYTK N/A
- EPS Growth
- TPG N/A
- CYTK N/A
- EPS
- TPG N/A
- CYTK N/A
- Revenue
- TPG $3,406,805,000.00
- CYTK $3,219,000.00
- Revenue This Year
- TPG N/A
- CYTK N/A
- Revenue Next Year
- TPG $16.57
- CYTK $710.83
- P/E Ratio
- TPG $2,777.14
- CYTK N/A
- Revenue Growth
- TPG 84.54
- CYTK N/A
- 52 Week Low
- TPG $39.16
- CYTK $44.49
- 52 Week High
- TPG $72.98
- CYTK $84.92
- Technical
- Relative Strength Index (RSI)
- TPG 55.66
- CYTK 38.82
- Support Level
- TPG $61.13
- CYTK $44.49
- Resistance Level
- TPG $66.61
- CYTK $48.45
- Average True Range (ATR)
- TPG 1.74
- CYTK 1.69
- MACD
- TPG 0.34
- CYTK -0.07
- Stochastic Oscillator
- TPG 97.52
- CYTK 22.08
About TPG TPG Inc.
TPG Inc is an alternative asset firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, and Market Solutions. TPG aims to build dynamic products and options for its clients while also instituting discipline and operational excellence across the investment and performance of its portfolio.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.